Scope of this summary
Adults with suspected or established chronic obstructive pulmonary disease, including stable longitudinal management and recognition of exacerbations. GOLD 2026 supplies the current comprehensive strategy; the ERS/ATS document supplies focused exacerbation-treatment recommendations. Alpha-1 antitrypsin deficiency, lung-volume procedures, transplantation and mechanical-ventilation protocols need specialist guidance.
The Bottom Line
- Suspect COPD from chronic respiratory symptoms and relevant exposure history, but confirm persistent airflow obstruction with post-bronchodilator spirometry rather than symptoms or imaging alone.
- After confirmation, assess symptom burden, exacerbation history, blood eosinophils where they inform inhaled-corticosteroid decisions, smoking and other exposures, oxygenation, nutrition, activity and comorbidity.
- Build maintenance treatment around long-acting bronchodilation; add or withdraw inhaled corticosteroid only in the clinical contexts defined by GOLD, balancing exacerbation benefit against pneumonia and other harms.
- Smoking treatment, vaccination, physical activity, inhaler education and pulmonary rehabilitation are core disease-modifying or function-preserving interventions rather than optional extras.
- Create an exacerbation plan and reassess after each event because frequent or severe exacerbations should trigger review of diagnosis, maintenance therapy, prevention and specialist needs.
Practical clinical workflow
1
Document tobacco, vaping, biomass and occupational exposure; characterize dyspnea, cough, sputum, infections and functional decline, and examine for cardiac disease, asthma, bronchiectasis and other mimics.
2
Obtain quality-assured post-bronchodilator spirometry; use chest imaging and additional testing to investigate atypical findings or comorbidity, not as a substitute for physiologic confirmation.
3
Select an inhaled regimen from symptoms and prior exacerbations, teach and observe device technique, address affordability, and record smoking treatment, vaccines and rehabilitation eligibility.
4
At follow-up, reassess symptoms, exacerbations, technique, adherence, adverse effects and new diagnoses before changing pharmacotherapy; repeat lung-function assessment when clinically useful.
5
For an exacerbation, assess severity and alternative emergencies, increase short-acting bronchodilator treatment, and use systemic corticosteroid, antibiotic, oxygen or ventilatory support only under the source-defined indications.
Safety boundaries and escalation
- New hypoxemia, altered mental status, exhaustion, hemodynamic instability, severe work of breathing, cyanosis or suspected pneumothorax, pneumonia, pulmonary embolism or acute heart failure requires emergency evaluation.
- ERS/ATS strongly recommends noninvasive ventilation for appropriate acute or acute-on-chronic hypercapnic respiratory failure; this decision requires monitored acute-care assessment.
- Prescribe oxygen to a measured target and reassess; excessive uncontrolled oxygen can worsen hypercapnia in susceptible patients, while chronic home oxygen requires separate eligibility testing.
- Do not start inhaled corticosteroid solely for a low eosinophil count or nonspecific wheeze, and do not stop systemic corticosteroid or antibiotic decisions from a generic page when illness severity or another infection changes the balance.
Localization
Use current GOLD strategy together with FDA product labels and US vaccine recommendations. US pulmonary-rehabilitation, oxygen and inhaler coverage varies by payer.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report2026 report and pocket guide 路 accessed 2026-08-20view source
- European Respiratory Society and American Thoracic SocietyManagement of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineDOI 10.1183/13993003.00791-2016 路 published 2017-03-15 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.